These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34171435)

  • 21. Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine?
    Cross S; Rho Y; Reddy H; Pepperrell T; Rodgers F; Osborne R; Eni-Olotu A; Banerjee R; Wimmer S; Keestra S
    BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34937701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine.
    Agharbi FZ; Eljazouly M; Basri G; Faik M; Benkirane A; Albouzidi A; Chiheb S
    Ann Dermatol Venereol; 2022 Mar; 149(1):56-57. PubMed ID: 34686374
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.
    Kant R; Dwivedi G; Zaman K; Sahay RR; Sapkal G; Kaushal H; Nyayanit DA; Yadav PD; Deshpande G; Singh R; Chaowdhary S; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34652440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine.
    Ahmer S; Bourke J; Ardakani NM
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35850789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC29. PubMed ID: 33646835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first cerebral MRI scan.
    Ikenberg B; Demleitner AF; Thiele T; Wiestler B; Götze K; Mößmer G; Lingor P
    Stroke Vasc Neurol; 2021 Dec; 6(4):668-670. PubMed ID: 34244448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute Arterial Occlusion Following ChAdOx1 nCov-19 (Oxford-AstraZeneca) Vaccination.
    Ali A; Rabouhans J; Salar T; Moghul S; Makkuni S; Browne T; Ahmed R; Syed I; Zaman A
    Cardiovasc Intervent Radiol; 2022 Mar; 45(3):398-401. PubMed ID: 35043242
    [No Abstract]   [Full Text] [Related]  

  • 28. Vaccine innovation model: A technology transfer perspective in pandemic contexts.
    Medeiros MZ; Soares PF; Fialho BC; Gauss L; Piran FS; Lacerda DP
    Vaccine; 2022 Aug; 40(33):4748-4763. PubMed ID: 35773123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case report of ChAdOx1 nCoV-19 vaccine-associated encephalitis.
    Takata J; Durkin SM; Wong S; Zandi MS; Swanton JK; Corrah TW
    BMC Neurol; 2021 Dec; 21(1):485. PubMed ID: 34903200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Potential Declining Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) on Inoculators With Nonsteroidal Anti-inflammatory Drug (NSAID) Intake.
    Yeh HF
    Clin Infect Dis; 2022 Mar; 74(4):753-754. PubMed ID: 34079995
    [No Abstract]   [Full Text] [Related]  

  • 31. Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford-AstraZeneca) vaccination.
    Robichaud J; Côté C; Côté F
    CMAJ; 2021 Aug; 193(34):E1341-E1344. PubMed ID: 34362727
    [No Abstract]   [Full Text] [Related]  

  • 32. Delayed local reactions after the first administration of the ChAdOx1 nCoV-19 vaccine.
    Shin E; Bae S; Jung J; Song WJ; Kwon HS; Kim HS; Kim SH; Kim TB; Cho YS; Lee JH
    Allergy; 2021 Nov; 76(11):3520-3522. PubMed ID: 34129694
    [No Abstract]   [Full Text] [Related]  

  • 33. Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine.
    Atta SN; Othman N; Babar M
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34969796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination.
    Crane P; Wong C; Mehta N; Barlis P
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34625447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine.
    Kumar R; Kodan P; Aggarwal R; Deepak GP; Trikha A
    QJM; 2022 Jun; 115(6):423. PubMed ID: 34297134
    [No Abstract]   [Full Text] [Related]  

  • 36. Response to: Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine.
    Niyas VKM; Arjun R
    QJM; 2022 Jun; 115(6):424-425. PubMed ID: 34297117
    [No Abstract]   [Full Text] [Related]  

  • 37. The Polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients.
    Sellaturay P; Gurugama P; Harper V; Dymond T; Ewan P; Nasser S
    Clin Exp Allergy; 2022 Jan; 52(1):12-17. PubMed ID: 34822190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breakthrough infections and waning immune responses with ChAdOx1 nCoV-19 or mRNA vaccine in healthcare workers.
    Lim SY; Jung J; Kim JY; Park S; Kwon JS; Park SY; Kim SK; Lim YJ; Kim EO; Bae S; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Lee N; Kim K; Shum D; Jee Y; Kim SH
    Clin Transl Med; 2022 Apr; 12(4):e804. PubMed ID: 35452187
    [No Abstract]   [Full Text] [Related]  

  • 39. A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
    Kim G; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH
    J Korean Med Sci; 2021 Nov; 36(43):e306. PubMed ID: 34751013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor?
    Essam R; Ehab R; Al-Razzaz R; Khater MW; Moustafa EA
    J Cosmet Dermatol; 2021 Dec; 20(12):3727-3729. PubMed ID: 34559937
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.